Drug-drug interactions between canagliflozin , a sodium glucose co-transporter 2 inhibitor approved for the management of type-2 diabetes mellitus , and an oral contraceptive ( OC ) , warfarin , and digoxin were evaluated in three phase 1 studies in healthy participants .